Home
About
Overview
Sharing Data
ORCID
Help
History (4)
Cognitive enhancers in the treatment of substance use disorders: clinical evidence.
Contribution of Epithelial Cell Dysfunction to the Pathogenesis of Chronic Rhinosinusitis with Nasal Polyps.
How Does the Use of Flavored Nicotine Vaping Products Relate to Progression Toward Quitting Smoking? Findings From the 2016 and 2018 ITC 4CV Surveys.
Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
See All 4 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cognitive enhancers in the treatment of substance use disorders: clinical evidence.
Cognitive enhancers in the treatment of substance use disorders: clinical evidence. Pharmacol Biochem Behav. 2011 Aug; 99(2):285-94.
View in:
PubMed
subject areas
Adrenergic Agents
Benzhydryl Compounds
Central Nervous System Stimulants
Cholinesterase Inhibitors
Cognition
Excitatory Amino Acid Agents
Humans
Neurotransmitter Agents
Nicotinic Agonists
Nootropic Agents
Substance-Related Disorders
authors with profiles
Kevin M Gray
Kathleen T. Brady
Bryan K. Tolliver